Back

The safety of apixaban compared to warfarin in hospitalized patients with acute kidney injury

14 March 2025 (08:45 - 18:30)
Organised by: Logo
Congress Presentation Part of: Late-breaking science Anticoagulants ACVC Premium Access ESC Acute CardioVascular Care 2025 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Doctor Lama Alfehaid

King Saud Bin Abdulaziz University for Health Sciences, Riyadh (Saudi Arabia)

4 More presentations in this session

Presentation thumbnail
Diuretic treatment in acute heart failure with volume overload guided by serial spot urine sodium assessment
Professor F. Verbrugge (Brussels, BE)
Slides Video
Presentation thumbnail
The influence of treatment delay on the benefit of a microaxial flow pump in patients with ST segment elevation myocardial infarction and cardiogenic shock
Professor C. Hassager (Copenhagen, DK)
Slides Video
Presentation thumbnail
Performance of the BNP and NTproBNP triage algorithm for AHF including the effect of renal dysfunction
Doctor D. Wussler (Basel, CH)
Slides Video
Presentation thumbnail
The Impella/mitral valve angle predicts early and late haemolysis in patients receiving Impella support
Doctor V. Galusko (London, GB)
Slides Video

Access the full session

Session thumbnail
Late-breaking science

The Event

Event poster

ESC Acute CardioVascular Care 2025

14 March - 15 March 2025
You may be interested in
thumbnail
Congress Presentation
Apixaban vs. warfarin for venous thromboembolism in renal impairment: a meta-analysis of efficacy and safety
thumbnail
Congress Presentation
Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants
thumbnail
Congress Presentation
Rivaroxaban or warfarin in atrial fibrillation and coronary stent implantation in real-world patients involving chronic kidney disease (REWRAPS): 5-year follow-up study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources